1. Home
  2. BGLC vs THAR Comparison

BGLC vs THAR Comparison

Compare BGLC & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BGLC
  • THAR
  • Stock Information
  • Founded
  • BGLC 2017
  • THAR 2017
  • Country
  • BGLC Malaysia
  • THAR United States
  • Employees
  • BGLC N/A
  • THAR N/A
  • Industry
  • BGLC Medical Specialities
  • THAR Biotechnology: Pharmaceutical Preparations
  • Sector
  • BGLC Health Care
  • THAR Health Care
  • Exchange
  • BGLC Nasdaq
  • THAR Nasdaq
  • Market Cap
  • BGLC 5.0M
  • THAR 5.5M
  • IPO Year
  • BGLC N/A
  • THAR 2022
  • Fundamental
  • Price
  • BGLC $6.41
  • THAR $1.86
  • Analyst Decision
  • BGLC
  • THAR Strong Buy
  • Analyst Count
  • BGLC 0
  • THAR 1
  • Target Price
  • BGLC N/A
  • THAR $17.00
  • AVG Volume (30 Days)
  • BGLC 2.7M
  • THAR 43.0K
  • Earning Date
  • BGLC 08-13-2025
  • THAR 08-08-2025
  • Dividend Yield
  • BGLC N/A
  • THAR N/A
  • EPS Growth
  • BGLC N/A
  • THAR N/A
  • EPS
  • BGLC N/A
  • THAR N/A
  • Revenue
  • BGLC $9,265,870.00
  • THAR N/A
  • Revenue This Year
  • BGLC N/A
  • THAR N/A
  • Revenue Next Year
  • BGLC N/A
  • THAR N/A
  • P/E Ratio
  • BGLC N/A
  • THAR N/A
  • Revenue Growth
  • BGLC N/A
  • THAR N/A
  • 52 Week Low
  • BGLC $2.01
  • THAR $0.95
  • 52 Week High
  • BGLC $15.60
  • THAR $6.39
  • Technical
  • Relative Strength Index (RSI)
  • BGLC 60.18
  • THAR 63.37
  • Support Level
  • BGLC $5.56
  • THAR $1.73
  • Resistance Level
  • BGLC $15.60
  • THAR $1.96
  • Average True Range (ATR)
  • BGLC 0.96
  • THAR 0.15
  • MACD
  • BGLC 0.52
  • THAR 0.04
  • Stochastic Oscillator
  • BGLC 29.46
  • THAR 85.71

About BGLC BioNexus Gene Lab Corp Common stock

BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.

About THAR Tharimmune Inc.

Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.

Share on Social Networks: